Jacobs Levy Equity Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-87,643	Closed	-$84K	–	1133
2018 Q3	$84K	Hold	87,643	–	–	﹤0.01%	966
2018 Q2	$213K	Buy	87,643 +7,722	+10%	+$18.9K	﹤0.01%	951
2018 Q1	$191K	Buy	79,921 +6,500	+9%	+$16.4K	﹤0.01%	935
2017 Q4	$176K	Buy	73,421 +11,700	+19%	+$32.4K	﹤0.01%	919
2017 Q3	$194K	Buy	61,721 +22,421	+57%	+$71.9K	﹤0.01%	869
2017 Q2	$158K	Buy	+39,300	New	+$171K	﹤0.01%	870
2016 Q2	–	Sell	-5,515	Closed	-$58K	–	1303
2016 Q1	$58K	Buy	+5,515	New	+$110K	﹤0.01%	1064

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

MFGP

Marshall Financial Group (Pennsylvania) Doylestown, Pennsylvania $364M AUM 12.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management's PTX Position: Q4 2018 in Review

Jacobs Levy Equity Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2018, closing a stake of 87,643 shares — an estimated $84K sold.

Jacobs Levy Equity Management first reported a position in PTX in Q1 2016 and held it in 7 quarters. The position peaked at $213K in Q2 2018. 32 funds tracked by Wall St. Rank hold PTX as of Q4 2018.

Jacobs Levy Equity Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 87,643 Pernix Therapeutics Holdings, Inc. shares in Q4 2018, an estimated $84K.
Jacobs Levy Equity Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's Pernix Therapeutics Holdings, Inc. position peaked at $213K in Q2 2018.
32 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2018, filed 14 Feb 2019.